Advertisement

ADVERTISEMENT

Kidney Cancer

Dr
Videos
Dr Lee Highlights Results of Nivolumab Plus Cabozantinib in Non-Clear Cell Kidney Cancer
07/01/2021
Chung-Han Lee, MD, Memorial Sloan Kettering Cancer Center, highlights the phase 2 clinical trial results of nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma, presented at the 2021 ASCO Annual Meeting.
Chung-Han Lee, MD, Memorial Sloan Kettering Cancer Center, highlights the phase 2 clinical trial results of nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma, presented at the 2021 ASCO Annual Meeting.
Chung-Han Lee, MD, Memorial...
07/01/2021
Oncology
News
Study Findings Support Surveillance Imaging Past 5 Years Postsurgery in RCC
11/18/2019
Findings from a post hoc analysis support the use of surveillance imaging beyond 5 years after surgical resection in patients with intermediate- to high-risk RCC.
Findings from a post hoc analysis support the use of surveillance imaging beyond 5 years after surgical resection in patients with intermediate- to high-risk RCC.
Findings from a post hoc...
11/18/2019
Oncology
News
Oblate-Covered Everolimus Reduces Stomatitis in Patients With Metastatic RCC
11/13/2019
Oblate-covered everolimus improved the incidence rate and reduced time to stomatitis grade ≥2 in patients with mRCC.
Oblate-covered everolimus improved the incidence rate and reduced time to stomatitis grade ≥2 in patients with mRCC.
Oblate-covered everolimus...
11/13/2019
Oncology
News
Individualized Axitinib Dosing Feasible for Metastatic RCC
09/27/2019
A phase 2 study suggests that individualized axitinib dosing is a feasible therapy option for metastatic RCC.
A phase 2 study suggests that individualized axitinib dosing is a feasible therapy option for metastatic RCC.
A phase 2 study suggests that...
09/27/2019
Oncology
News
Nivolumab–Ipilimumab Combo Shows Long-Term Benefit in Advanced RCC
09/14/2019
Study findings show the long-term benefits of combining nivolumab therapy plus ipilimumab in treatment-naïve advanced RCC.
Study findings show the long-term benefits of combining nivolumab therapy plus ipilimumab in treatment-naïve advanced RCC.
Study findings show the...
09/14/2019
Oncology
News
Experts Validate Classifier That Can Predict Recurrence Risk in Clear-Cell RCC
04/03/2019
Researchers have created and validated a classifier that can predict whether recurrence risk is high or low in patients with localized, clear-cell RCC.
Researchers have created and validated a classifier that can predict whether recurrence risk is high or low in patients with localized, clear-cell RCC.
Researchers have created and...
04/03/2019
Oncology
News
Cabozantinib Shows Promise in Treatment of Non-Clear-Cell RCC
03/07/2019
Results from a recent study suggest that cabozantinib provides significant clinical benefit to certain patients with non-clear-cell RCC.
Results from a recent study suggest that cabozantinib provides significant clinical benefit to certain patients with non-clear-cell RCC.
Results from a recent study...
03/07/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use